Mr. Higgins has 15 years of experience as a biopharmaceuticals analyst. His current focus is on therapeutic companies, including pain/addiction, anti-infectives, neurological and drug delivery. Prior to joining Ladenburg Thalmann, he was a Managing Director, Senior Research Analyst at ROTH Capital Partners as well as Rodman & Renshaw Capital LLC. Mr. Higgins began his career in equity research at Dafna Capital in Beverly Hills, CA where he focused on drug launches of biopharmaceutical companies, which followed ten years in pharmaceutical marketing at Procter & Gamble Pharmaceuticals. Mr. Higgins earned his Bachelor of Science in Finance from the University of Wisconsin-Stevens Point and his MBA with a focus on Finance and Investment Analysis from Marquette University.